Filing Flows › Syndax Pharmaceuticals (SNDX) › Q3 2026 › vs Q2 2026
Syndax Pharmaceuticals (SNDX) Q3 2026 vs Q2 2026 (quarter over quarter)
Syndax Pharmaceuticals's revenue rose $10.5M (+14%) from $72.8M in Q2 2026 to $83.3M in Q3 2026. The biggest changes: Product +$6.0M (+11%); Collaboration Revenue +$4.5M (+25%).
Syndax Pharmaceuticals, Q3 2026: revenue $83.3M (+82% year over year), operating margin -50.3%, net loss $49.4M, operating cash flow −$27.3M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Product | $60.7M | $54.7M | $6.0M | +11% |
| Collaboration Revenue | $22.6M | $18.1M | $4.5M | +25% |
| Revenue | $83.3M | $72.8M | $10.5M | +14% |
| Net loss | $49.4M | $49.4M | $70K | +0.1% |
| Costs & expenses | $133M | $122M | $10.6M | +9% |
| Operating costs | $125M | $113M | $12.4M | +11% |
| Interest & other, net | $7.5M | $9.4M | −$1.8M | -20% |
| Research & development | $67.5M | $68.0M | −$555K | -0.8% |
| General & admin | $43.7M | $41.5M | $2.2M | +5% |
| Other operating costs | $14.0M | $3.2M | $10.8M | +336% |
| Operating cash sources | $49.4M | $49.4M | $70K | +0.1% |
| Depreciation | $6.0M | $5.0M | $1.0M | +20% |
| Share-based compensation | $15.3M | $14.0M | $1.3M | +9% |
| Working capital & other | $892K | $78K | $814K | 11× |
| Cash used in operations | $27.3M | $30.3M | −$3.0M | -10% |
| Net loss absorbed | $49.4M | $49.4M | $70K | +0.1% |
Questions
How much did Syndax Pharmaceuticals's revenue grow quarter over quarter in Q3 2026?
Syndax Pharmaceuticals's revenue rose $10.5M (+14%) from $72.8M in Q2 2026 to $83.3M in Q3 2026.
What drove Syndax Pharmaceuticals's revenue change in Q3 2026?
Product +$6.0M (+11%); Collaboration Revenue +$4.5M (+25%).